Roivant Sciences Ltd. last reported quarterly results on Aug 6, 2026, for Q1 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.4 million (-33.5% year over year) and diluted EPS of -$0.26. It usually reports 2–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 9, 2026.
Results for Q2 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 10, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 2–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q1 FY2026
ended Jun 30, 2026
|
1
-33.5%
|
-190
+15.0%
|
-0.26
+21.2%
|
|
Apr 2, 2026
2 days after quarter end
|
Q4 FY2025
ended Mar 31, 2026
|
3
-66.7%
|
303
+246.7%
|
0.42
+244.6%
|
|
Feb 6, 2026
37 days after quarter end
|
Q3 FY2025
ended Dec 31, 2025
|
2
-77.8%
|
-266
-257.0%
|
-0.38
-265.2%
|
|
Nov 10, 2025
41 days after quarter end
|
Q2 FY2025
ended Sep 30, 2025
|
2
-64.9%
|
-114
+50.7%
|
-0.17
+45.2%
|
|
Aug 11, 2025
42 days after quarter end
|
Q1 FY2025
ended Jun 30, 2025
|
2
-72.8%
|
-223
-334.4%
|
-0.33
-375.0%
|
|
May 29, 2025
59 days after quarter end
|
Q4 FY2024
ended Mar 31, 2025
|
8
-16.1%
|
-206
-36.6%
|
-0.29
-64.4%
|
|
Feb 10, 2025
41 days after quarter end
|
Q3 FY2024
ended Dec 31, 2024
|
9
-42.1%
|
169
-96.7%
|
0.23
-96.2%
|
|
Nov 12, 2024
43 days after quarter end
|
Q2 FY2024
ended Sep 30, 2024
|
4
+22.7%
|
-230
+24.4%
|
-0.31
+22.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ROIV (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Bermuda
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1635088
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.